| Trial ID | Outcome | High risk of bias (category A)a | High risk of bias (category D)b | High risk of bias (category E)c | High risk of bias (category G)d |
| Bilezikian 2013 | Anthropometric measures | No | No | Yes | No |
| Intervention failure | No | Yes | No | No | |
| Campbell 1994 | Lactic acidosis | No | No | No | Yes |
| Serious adverse events | No | Yes | No | No | |
| Severe hypoglycaemia | No | Yes | No | No | |
| Derosa 2003 | All‐cause mortality | No | No | Yes | No |
| Anthropometric measures | No | Yese | No | No | |
| Glycaemic control | No | Yese | No | No | |
| Derosa 2004 | ND | ||||
| Derosa 2009 | All‐cause mortality | No | No | Yes | No |
| Serious adverse events | No | Yese | No | No | |
| Severe hypoglycaemia | No | Yese | No | No | |
| Glycaemic control | No | Yese | No | No | |
| Anthropometric variables | No | Yese | No | No | |
| Erem 2014 | ND | ||||
| Kahn 2006 | Health‐related quality of life | No | Yes | No | No |
| Kiyici 2009 | ND | ||||
| Onuchin 2010 | All‐cause mortality | No | No | Yes | No |
| Serious adverse events | No | No | Yes | No | |
| Severe hypoglycaemia | No | No | No | Yes | |
| Pfützner 2011 | Anthropometric measures | No | Yese | Yes | No |
| Rahman 2011 | All‐cause mortality | No | No | Yes | No |
| Serious adverse events | No | No | Yes | No | |
| Schernthaner 2004 | Serious adverse events | No | No | Yes | No |
| Anthropometric measures | No | Yese | Yes | No | |
| Schweizer 2007 | Non‐fatal myocardial infarction | No | No | No | Yes |
| Serious adverse events | No | Yese, f | No | No | |
| Severe hypoglycaemia | No | Yese, f | No | No | |
| Glycaemic controlg | No | Yese | No | No | |
| Anthropometric measuresg | No | Yese | No | No | |
| Intervention failure | No | No | Yes | No | |
| Teupe 1991 | All‐cause mortality | No | No | Yes | No |
| Serious adverse events | No | No | Yes | No | |
| Lactic acidosis | No | No | No | Yes | |
| UKPDS 34 1998 | All‐cause mortality | No | Yes | No | No |
| Serious adverse events | No | Yes | No | No | |
| Health‐related quality of life | No | Yes | No | No | |
| Cardiovascular mortality | No | Yes | No | No | |
| Non‐fatal myocardial infarction | No | Yes | No | No | |
| Non‐fatal stroke | No | Yes | No | No | |
| End‐stage renal disease | No | Yes | No | No | |
| Blindness | No | Yes | No | No | |
| Umpierrez 2014 | ND | ||||
| Williams‐Herman 2010 | Intervention failure | No | Yese | No | No |
| Yamanouchi 2005 | All‐cause mortality | No | No | Yes | No |
| Serious adverse events | No | No | Yes | No | |
| Severe hypoglycaemia | No | No | No | Yes | |
|
aClear that outcome was measured and analysed; trial report states that outcome was analysed but reports only that result was not significant
(Classification 'A', table 2, Kirkham 2010)
bClear that outcome was measured and analysed; trial report states that outcome was analysed but report no results
(Classification 'D', table 2, Kirkham 2010)
cClear that outcome was measured but was not necessarily analysed; judgement says likely to have been analysed but not reported due to non‐significant results (Classification 'E', table 2, Kirkham 2010)
dUnclear whether outcome was measured; not mentioned, but clinical judgement says likely to have been measured and analysed but not reported on the basis of non‐significant results (Classification 'G', table 2, Kirkham 2010)
eOutcome reported in an inadequate format that could not be used in our meta‐analysis
fUnclear whether participants with the outcomes in the initial 52‐week study were being added to the results from the extension period
gOutcomes measured in the extension period of 52 weeks ND: none detected; ORBIT: Outcome Reporting Bias In Trials; UKPDS: United Kingdom Prospective Diabetes Study. | |||||